5Rumpianesi F,Morandotti G,Sperning R,et al.In vitro activity of azithromycin against Chlamydia trachomatis,Ureaplasma urealyticum and Mycoplasma hominis in comparison with erythromycin,roxithromycin and minocycline[J].J Chemother,1993,5(3):155-158.
6Wakes KB,Crabb DM ,Xuc B,et al. In vitro Susceptibilitics to and bactericidal activitics garenoxacin (BM S-284756) and other antimicrobial agent against human mycoplasmas and ureaplasmas [J]. Antimicrob Agents Chemother,2003,47(1) : 161-165.
7Culley CM ,Lacy MK,Klutman N ,et al, Moxifloxacin clinical efficacy and safety[J]. An J Healthsyst Pharm,2001,58(5) :379-388.
8Breilh D,Jougon J,Djaharouti S,et al. Diffusion of oral and intravenous 400mg Once daily moxifloxacin into Lungtissuc at pharmacokinetic steedy-state[]. J Chemother, 2003,15:558-562.
9Petra Bago,Aleksandar Vcev,Monika Tomic,Marjan Ro?ankovic,Marinko Maru?i?,Josip Bago. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial[J] 2007,Wiener klinische Wochenschrift(11-12):372～378
